FindTrial
Sign In

Effect of Agnikarma in fistula-in -ano

Effect of Agnikarma in Perianal Subcutaneous fistula

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/041511
Enrollment
23
Registered
2022-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system Health Condition 2: K928- Other specified diseases of the digestive system

Interventions

None listed

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with subcutaneous perianal fistula with tract length less than 5cm

Exclusion criteria

Exclusion criteria: Congenital fistula Intersphincteric,complex and high anal fistula Subjects with systemic diseases like Diabetes Mellitus,Bleeding disorders, Cardiac diseases,AIDS, Tuberculosis, Actinomycosis, Crohnâ??s disease, Ulcerative Colitis and CA rectum.

Design outcomes

Primary

MeasureTime frame
Discharge Healing time in number of weeks Recurrence rateTimepoint: 0th day,7th day,14th day,21th day,28th day,35 th day and 42 th day—

Secondary

MeasureTime frame
recurrence rateTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Merin C Joseph

Government Ayurveda college,Trivandrum

drpathrosebenedict@gmail.com9447820024

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026